(Q34225622)

31 July 2017

title

Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up (English)

1 reference

inflammatory bowel diseases

31 July 2017

main subject

0 references

author name string

Renato Caviglia

1

1 reference

31 July 2017

Mentore Ribolsi

2

1 reference

31 July 2017

Marina Rizzi

3

1 reference

31 July 2017

Sara Emerenziani

4

1 reference

31 July 2017

Maria Laura Annunziata

5

1 reference

31 July 2017

Michele Cicala

6

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 October 2007

1 reference

World Journal of Gastroenterology

31 July 2017

published in

1 reference

31 July 2017

volume

13

1 reference

31 July 2017

issue

39

1 reference

31 July 2017

page(s)

5238-5244

1 reference

Review article: Infliximab therapy for inflammatory bowel disease--seven years on

31 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171306

Infliximab for induction and maintenance therapy for ulcerative colitis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171306

Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171306

Guidelines for the management of inflammatory bowel disease in adults

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171306

Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171306

Infliximab maintenance therapy for fistulizing Crohn's disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171306

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171306

Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171306

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171306

Management of Crohn's disease in adults

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171306

Infliximab for the treatment of fistulas in patients with Crohn's disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171306

Inflammatory bowel disease: etiology and pathogenesis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171306

Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171306

Malignancy in Crohn's disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171306

Inflammatory bowel disease (2)

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171306

Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171306

Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171306

Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171306

Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171306

Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171306

Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171306

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171306

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171306

The incidence and management of infusion reactions to infliximab: a large center experience

28 October 2018

1 reference

12 December 2020

Preliminary report: cyclosporin in treatment of severe active ulcerative colitis

1 reference

12 December 2020

Extraintestinal cancers in inflammatory bowel disease

1 reference

12 December 2020

Infliximab in Crohn's disease: first anniversary clinical experience

1 reference

12 December 2020

Cancer risk in patients with inflammatory bowel disease: a population-based study

1 reference

12 December 2020

The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study

1 reference

12 December 2020

Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.

1 reference

12 December 2020

Identifiers

DOI

10.3748/WJG.V13.I39.5238

1 reference

31 July 2017

1 reference

31 July 2017

1 reference